Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2025)

Historic FCF Margin for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to 101.06%.

  • Arcturus Therapeutics Holdings' FCF Margin fell 438400.0% to 101.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 60.09%, marking a year-over-year decrease of 216700.0%. This contributed to the annual value of 39.65% for FY2024, which is 270600.0% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported FCF Margin of 101.06% as of Q3 2025, which was down 438400.0% from 20.33% recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' FCF Margin peaked at 479.64% during Q2 2023, and registered a low of 2030.47% during Q1 2021.
  • In the last 5 years, Arcturus Therapeutics Holdings' FCF Margin had a median value of 73.96% in 2023 and averaged 345.52%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -15724200bps in 2021, then surged by 15245300bps in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' FCF Margin (Quarter) stood at 752.76% in 2021, then surged by 113bps to 97.6% in 2022, then plummeted by -105bps to 4.87% in 2023, then skyrocketed by 74bps to 1.25% in 2024, then tumbled by -8001bps to 101.06% in 2025.
  • Its FCF Margin was 101.06% in Q3 2025, compared to 20.33% in Q2 2025 and 120.06% in Q1 2025.